<DOC>
	<DOC>NCT02087423</DOC>
	<brief_summary>A study to assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in terms of efficacy, safety and tolerability</brief_summary>
	<brief_title>A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer</brief_title>
	<detailed_description>This study is designed to investigate the efficacy, safety, tolerability of a new drug, MEDI4736, in patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer. MEDI4736 will be investigated in patients who have received at least two prior treatment regimens including one platinum-based chemotherapy</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Aged at least 18 years. Documented evidence of NSCLC (stage IIIB/IV disease) Disease progression or recurrence after both a platinumbased chemotherapy and at least 1 additional regimen for treatment of NSCLC World Health Organisation (WHO) Performance Status of 0 or 1 Estimated life expectancy of more than 12 weeks Patient's tumour sample must be PDL1 positive (≥25%of tumour cells with membrane staining (Cohort 1 and 2) or PDL1 positive with ≥90% of tumour cells with membrane staining (Cohort 3)) Prior exposure to any antiPD1 or antiPDL1 antibody Brain metastases or spinal cord compression or unless asymptomatic, treated and stable (not requiring steroids). Active or prior autoimmune disease or history of immunodeficiency Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV. Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris. Any unresolved toxicity CTCAE &gt;Grade 2 from previous anticancer therapy. Any prior Grade ≥3 immunerelated adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE &gt;Grade 1 Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Locally advanced, metastatic, Non-Small Cell Lung Cancer, MEDI4736, PD-L1</keyword>
</DOC>